Wall Street analyst estimates for Soligenix, Inc. (SNGX): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Soligenix, Inc., a biopharmaceutical firm in its advanced development stages, concentrates on bringing innovative products to market within the United States, specifically targeting rare illnesses. The company's operations are divided into two main divisions: Specialized BioTherapeutics and Public Health Solutions.
Analyst Consensus
| Strong Buy | 0 |
| Buy | 5 |
| Hold | 3 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 8 |
| Avg rating (1-5) | 0.62 |
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-06 | $-0.12 | ||
| 2026-08-07 | $-0.12 | $-0.15 | +22.6% |
| 2026-05-08 | $-0.28 | $-0.30 | +6.7% |
| 2026-04-03 | $0.32 | $-0.27 | +218.5% |
| 2025-11-07 | $-0.58 | $-0.63 | +7.9% |
| 2025-08-14 | $-0.82 | $-0.79 | -3.8% |
| 2025-05-09 | $-1.06 | $-0.67 | -58.2% |
| 2025-03-21 | $-1.14 | $-0.95 | -20.0% |
Valuation Ratios
| Price / Book | 0.86 |
| EV / EBITDA | 0.36 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $10.4M | $5.4M | $5.2M | $3.2M | $1.9M | $33351 | $250000 | 0 | 0 | 0 |
| Cost of Revenue | $8.4M | $4.3M | $4.6M | $3.6M | $1.8M | $728640 | $550822 | $742048 | $119371 | 0 |
| Gross Profit | $2.0M | $1.1M | $643733 | -$351776 | $109584 | -$695289 | -$300822 | -$742048 | -$119371 | 0 |
| Research & Development | $4.3M | $5.5M | $6.8M | $8.1M | $14.8M | $8.2M | $7.9M | $3.3M | $5.2M | $7.5M |
| Selling, General & Admin | $3.4M | $3.2M | $3.0M | $3.5M | $4.3M | $5.0M | $6.7M | $4.5M | $4.2M | $4.4M |
| Operating Expenses | $7.7M | $8.0M | $8.4M | $10.2M | $18.7M | $12.4M | $13.9M | $7.0M | $9.3M | $11.8M |
| Operating Income | -$5.7M | -$7.6M | -$9.1M | -$10.5M | -$18.6M | -$13.1M | -$14.2M | -$7.7M | -$9.4M | -$11.8M |
| EBITDA | -$5.6M | -$7.5M | -$9.0M | -$10.1M | -$18.5M | -$12.5M | -$14.1M | -$7.7M | -$9.5M | -$11.6M |
| Interest Expense | 0 | 0 | 0 | 0 | $10882 | $904502 | $822611 | $49129 | 0 | 0 |
| Pre-tax Income | -$3.8M | -$7.6M | -$8.9M | -$10.0M | -$18.5M | -$13.4M | -$15.0M | -$7.9M | -$8.7M | -$11.6M |
| Income Tax | -$530000 | -$417000 | 0 | -$610676 | -$836893 | -$864742 | -$1.2M | -$1.8M | -$409114 | -$506615 |
| Net Income | -$3.2M | -$7.1M | -$8.9M | -$9.4M | -$17.7M | -$12.6M | -$13.8M | -$6.1M | -$8.3M | -$11.1M |
| EPS | $-223.20 | $-278.40 | $-162.09 | $-115.88 | $-154.45 | $-67.54 | $-76.96 | $-12.66 | $-4.98 | $-2.14 |
| EPS (Diluted) | $-321.60 | $-278.40 | $-162.09 | $-115.88 | $-154.45 | $-75.06 | $-76.89 | $-12.66 | $-4.98 | $-2.14 |
| Shares Outstanding (Diluted) | $14932 | $25601 | $54909 | $80735 | $114529 | $185797 | $179459 | $484877 | $1.7M | $5.2M |
Price
| Price | $0.36 |
| Market Cap | $5M |
| Exchange | NASDAQ |
| Country | US |
Related companies: CANF · CMND · ENSC · KZIA · OGEN · QLGN · SILO
Explore sector: Healthcare · Biotechnology
More sections of SNGX: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks